About the Company
Since long before the outbreak of COVID-19, antibiotic resistant bacteria have created a “silent pandemic” that now poses a threat to life as we know it.
Antimicrobial resistance (“AMR”) occurs when bacteria develop the ability to defeat the drugs designed to kill them or to stop their growth.
AMR infections contribute to the death approximately 5,000,000 people a year globally and if no action is taken, that number will continue to grow exponentially.
Cūrza has the technology to address this pandemic.
Cūrza has developed a platform of distinctly unique compounds to attack the problem of AMR for some of the world’s worst antibiotic-resistant bacteria by selectively targeting a highly conserved site on the bacterial ribosome that has previously been undrugged.
Cūrza is a leader in fighting AMR and has received non-dilutive funding from the National Institute of Health (“NIH”), the Defense Threat Reduction Agency (“DTRA”), and CARB-X. Furthermore, Cūrza was one of the first U.S. recipients of investment from the Novo Holdings’ REPAIR Impact Fund, whose stated mission it to “increase humanity’s therapeutic arsenal in the fight against antimicrobial resistance.